Home » Archive

Drug Development

Drug Development, News, Syndication, Xconomy »

MediciNova Raises Capital Through $20M Stock Purchase Agreement

Posted by sandiegobiotech August 20th, 2012 .
No Comments

Aspire Capital, a Chicago-based fund that invests directly in public companies, has agreed to invest as much as $20 million in San Diego-based MediciNova (NASDAQ: MNOV) over the next two years….

[[Click headline to continue reading.]]

More...

Drug Development, News, Syndication, Xconomy »

Halozyme Says Roche Work Unaffected by FDA Concerns over HyQ Program

Posted by sandiegobiotech August 6th, 2012 .
No Comments

San Diego’s Halozyme Therapeutics (NASDAQ: HALO) told analysts and investors today it cannot provide a new timeline for its derailed HyQ program until company officials can meet with FDA regulators….

[[Click headline to continue reading.]]

More...

Drug Development, Drug Discovery, News, Syndication, Xconomy »

Xconomist of the Week: John Reed on Sanford-Burnham’s Drug Pipeline

Posted by sandiegobiotech August 3rd, 2012 .
No Comments

In the decade since John Reed stepped in as chief executive, San Diego’s Sanford-Burnham Medical Research Institute has basically doubled in size. The nonprofit research facility has added a campus…

[[Click headline to continue reading.]]

More...

Drug Development, News, Syndication, Xconomy »

Regulatory Concerns Over Halozyme’s Flagship Product Trigger Selloff

Posted by sandiegobiotech August 1st, 2012 .
No Comments

Shares of Halozyme Therapeutics (NASDAQ: HALO) plunged by more than 55 percent this evening, after the 14-year-old biopharmaceutical said FDA regulators have raised concerns about the potential…

[[Click headline to continue reading.]]

More...

Drug Development, News, Syndication, Xconomy »

Sophiris Moves to Unlock Blockbuster Potential in New Prostate Drug

Posted by sandiegobiotech July 10th, 2012 .
No Comments

In the vintage tic-tac-toe TV game show, The Hollywood Squares, one of the classic funny moments occurred when host Peter Marshall asks the question: “True or false—a pea can last as long as 5,000…

[[Click headline to continue reading.]]

More...

Drug Development, News, Syndication, Xconomy »

SD Life Sciences Roundup: Arena, PatientSafe, MEI Pharma, & More

Posted by sandiegobiotech June 28th, 2012 .
No Comments

Here’s my roundup of new developments from San Diego’s life sciences cluster over the past week. —After initially rejecting a new drug application from San Diego’s Arena Pharmaceuticals (NASDAQ:…

[[Click headline to continue reading.]]

More...

Biotechnology, Drug Development, Featured, Medical Device, SDBN Blog »

INNOVATION: Finding the way from ordinary to extraordinary

Posted by Jessica Yingling June 12th, 2012 .
No Comments

The biggest question in entrepreneurship is how does one take an idea and make it reality, make it something that’s tangible and positively affects an individual and society as a whole. This was the theme at March’s SDBN networking event with Organovo, sponsored by Invetech.
Invetech helps companies translate innovations into breakthrough products.  They work with diagnostics, life sciences, medical devices, industrial, consumer and clean-tech industries.  Based in Australia, Invetech opened an office in San Diego in 2008 and has worked with a number of local companies including Organovo.
From idea to …

More...

Drug Development, News, Syndication, Xconomy »

SD Biotech Roundup: Wireless Sensor Prize, Zogenix, Sangart, & More

Posted by sandiegobiotech May 31st, 2012 .
No Comments

The X Prize Foundation’s Peter Diamandis came to San Diego to announce the formation of a new incentive prize competition, while a variety of companies disclosed new funding deals. It’s all part of…

[[Click headline to continue reading.]]

More...

Drug Development, News, Syndication, Xconomy »

Safety Analyses Lead Sangart to Move Ahead with ‘Oxygen Therapeutic’

Posted by sandiegobiotech May 28th, 2012 .
No Comments

Encouraging results in a second mid-stage trial of an oxygen-carrying compound has prompted San Diego’s Sangart to draw on an additional $50 million from Leucadia National (NYSE: LUK), a diversified…

[[Click headline to continue reading.]]

More...

Drug Development, News, Syndication, Xconomy »

SD Life Sciences Roundup: Takeda Consolidates, Startups Raise Cash

Posted by sandiegobiotech May 24th, 2012 .
No Comments

It’s been a busy week for startup funding, with Obalon Therapeutics, Aperio Technologies, Topera, and Ivera Medical closing on financing deals. We’ve also got drug development news from Ocera…

[[Click headline to continue reading.]]

More...